Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Capitol Capsule: Fights Over Interpretation Of Biosimilars Law: Disruption To Market's Future?

This article was originally published in Scrip

Executive Summary

With some of the most complicated questions not likely to be resolved by the courts for potentially three to five years over the interpretation of various provisions in the extremely complex US biosimilars law – and the likelihood many more disputes will arise for years to come beyond the expected patent litigation – will some firms hold back or even avoid the area altogether, leading to the American market not being as robust as it could be?



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts